Patents by Inventor Philippe G. Nantermet

Philippe G. Nantermet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
    Patent number: 7820674
    Abstract: The present invention is directed to aminomethyl compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: October 26, 2010
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Philippe G. Nantermet, Hemaka A. Rajapakse, Harold G. Selnick, Shaun R. Stauffer
  • Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
    Patent number: 7816378
    Abstract: The present invention is directed to cyclic ketal compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: October 19, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Philippe G. Nantermet, Joseph P. Vacca
  • BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20100210693
    Abstract: The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: May 3, 2010
    Publication date: August 19, 2010
    Inventors: Philippe G. Nantermet, Hemaka Anthony Rajapakse, Harold G. Selnick
  • EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER
    Publication number: 20100197688
    Abstract: The present invention is directed to compounds of generic formula (I) which are inhibitors of ephrin A4. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases regulated by the EphA4 RTK signaling, such as neurological and neurodegenerative disorders and cancer.
    Type: Application
    Filed: May 28, 2009
    Publication date: August 5, 2010
    Inventors: Philippe G. Nantermet, Hamaka A. Rajapakse, Takeshi Sagara, John M. Sanders, Hong Zhu
  • EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER
    Publication number: 20100113415
    Abstract: The present invention is directed to compounds of generic formula (I) which are inhibitors of ephrin A4. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases regulated by the EphA4 RTK signaling, such as neurological and neurodegenerative disorders and cancer.
    Type: Application
    Filed: May 28, 2009
    Publication date: May 6, 2010
    Inventors: Hemaka A. Rajapakse, Keith P. Moore, Philippe G. Nantermet, John M. Sanders, Sophie Parmentier-Batteur, Robert J. Mark
  • Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
    Patent number: 7678783
    Abstract: The present invention is directed to macrocyclic tertiary amine compounds represented by general formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: March 16, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Philippe G. Nantermet, Hemaka A. Rajapakse, Harold G. Selnick, Stacey Lindsley, Keith P. Moore, Shawn J. Stachel
  • MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20100029701
    Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: October 2, 2007
    Publication date: February 4, 2010
    Inventors: Philippe G. Nantermet, M. Katharine Holloway, Keith P. Moore, Shaun R. Stauffer
  • Cyclic Ketal Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
    Publication number: 20090176836
    Abstract: The present invention is directed to cyclic ketal compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: July 28, 2006
    Publication date: July 9, 2009
    Inventors: Philippe G. Nantermet, Joseph P. Vacca
  • Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
    Publication number: 20090170830
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: July 28, 2006
    Publication date: July 2, 2009
    Inventor: Philippe G. Nantermet
  • Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease
    Patent number: 7550481
    Abstract: The present invention is directed to phenylamide and pyridylamide derivative compounds of which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: June 23, 2009
    Assignee: Merck & Co., Inc.
    Inventors: James C. Barrow, Craig A. Coburn, Philippe G. Nantermet, Harold G. Selnick, Shawn J. Stachel, Matthew G. Stanton, Shaun R. Stauffer, Linghang Zhuang, Jennifer R. Davis
  • Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
    Publication number: 20080269302
    Abstract: The present invention is directed to macrocyclic tertiary amine compounds represented by general formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: November 14, 2005
    Publication date: October 30, 2008
    Applicant: MERCK & CO., INC.
    Inventors: Philippe G. Nantermet, Hemaka A. Rajapakse, Harold G. Selnick, Stacey Lindsley, Keith P. Moore, Shawn J. Stachel
  • Aminomethyl Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
    Publication number: 20080153846
    Abstract: The present invention is directed to aminomethyl compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: January 13, 2006
    Publication date: June 26, 2008
    Inventors: Craig A. Coburn, Philippe G. Nantermet, Hemaka A. Rajapakse, Harold G. Selnick, Shaun R. Stauffer
  • Tertiary Carbinamines Having Substituted Heterocycles Which Are Active As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease
    Publication number: 20080139538
    Abstract: The present invention is directed to tertiary carbinamine compounds having substituted heterocycles, which are inhibitors of the beta-secretase enzyme, and are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: January 13, 2006
    Publication date: June 12, 2008
    Inventors: Georgia B. McGaughey, Philippe G. Nantermet, Hemaka A. Rajapakse, Shaun R. Stauffer
  • Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease
    Patent number: 7354942
    Abstract: The present invention is directed to benzylether and benzylamino derivative compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: April 8, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Philippe G. Nantermet, Hemaka A. Rajapakse, Harold G. Selnick, Shaun R. Stauffer, Mary Beth Young
  • Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
    Patent number: 7348448
    Abstract: The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: March 25, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Philippe G. Nantermet, Hemaka Anthony Rajapakse, Harold G. Selnick
  • Thrombin inhibitors
    Patent number: 7144899
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure Formula (I): wherein u is CH or N; Q is 1)—N(R25)CH(R30)— wherein the nitrogen atom is attached to R1, and R25 and R30 are independently selected from the group consisting of hydrogen, C3-6cycloalkyl, and C1-6alkyl, or 2) wherein the nitrogen atom is attached to R1, and m is 0, 1, or 2
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: December 5, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Harold G. Selnick, Mary Beth Young, Philippe G. Nantermet, James C. Barrow, Peter D. Williams, Terry A. Lyle, Donnette D. Staas, Kenneth J. Stauffer, Philip E. Sanderson
  • Thrombin inhibitors
    Patent number: 7084134
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: August 1, 2006
    Assignee: Merk & Co., Inc.
    Inventors: James C. Barrow, Philippe G. Nantermet, Harold G. Selnick
  • Thrombin inhibitors
    Patent number: 7026324
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein R2 is R3 is selected from the group consisting of 1) hydrogen, 2) halogen, 3) C1–4 alkyl, 4) C3–7 cycloalkyl, 5) CF3, 6) OCF3, 7) C1–4 alkoxy, and 8) cyano; and R12 is a 5-membered heteroaryl ring having 2, 3, or 4 heteroatoms, provided that at least 1 heteroatom is N, and at most 1 of the heteroatoms is S, said ring being unsubstituted or substituted, at any one ring atom, with CH3 .
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: April 11, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mary Beth Young, Philippe G. Nantermet, Harold G. Selnick, Peter D. Williams
  • Thrombin inhibitors
    Publication number: 20040097730
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein R2 is R3 is selected from the group consisting of 1) hydrogen, 2) halogen, 3) C 1-4 alkyl, 4) C 3-7 cycloalkyl, 5) CF3, 6) OCF3, 7) C 1-4 alkoxy, and 8) cyano; and R12 is a 5-membered heteroaryl ring having 2, 3, or 4 heteroatoms, provided that at least 1 heteroatom is N, and at most 1 of the heteroatoms is S, said ring being unsubstituted or substituted, at any one ring atom, with CH3.
    Type: Application
    Filed: August 1, 2003
    Publication date: May 20, 2004
    Inventors: Mary Beth Young, Philippe G. Nantermet, Harold G. Selnick, Peter D. Williams
  • Thrombin inhibitors
    Publication number: 20040073025
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure Formula (I): wherein u is CH or N; Q is 1)—N(R25)CH(R30)—wherein the nitrogen atom is attached to R1, and R25 and R30 are independently selected from the group consisting of hydrogen, C3-6cycloalkyl, and C1-6alkyl, or 2) wherein the nitrogen atom is attached to R1, and m is 0, 1, or 2.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 15, 2004
    Inventors: Harold G Selnick, Mary Beth Young, Philippe G Nantermet, James C Barrow, Peter D Williams, Terry A Lyle, Donnette D Staas, Kenneth J Stauffer, Philip E Sanderson